Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Kestra Medical Technologies has received a consensus rating of "Moderate Buy" from seven brokerage firms, with five analysts recommending a buy and one each for sell and hold.
• The company's stock price target among analysts is $27.33, and its shares recently rose by 1.2%, opening at $23.27.
• Kestra Medical Technologies reported a quarterly EPS of ($0.46), which surpassed analyst expectations, along with revenues of $19.37 million for the quarter.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $27.3333.

A number of equities research analysts recently commented on KMTS shares. Wall Street Zen cut shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research report on Sunday, September 28th. Weiss Ratings reissued a "sell (d)" rating on shares of Kestra Medical Technologies in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company decreased their target price on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a research report on Thursday, July 17th.

Kestra Medical Technologies Stock Up 1.2%

NASDAQ KMTS opened at $23.27 on Friday. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.23. The firm's 50 day moving average price is $20.33 and its 200-day moving average price is $20.15. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $27.71.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings data on Thursday, September 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.20. The business had revenue of $19.37 million for the quarter, compared to the consensus estimate of $17.68 million. Kestra Medical Technologies has set its FY 2026 guidance at EPS.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC purchased a new stake in Kestra Medical Technologies during the first quarter valued at approximately $1,869,000. Eventide Asset Management LLC purchased a new position in shares of Kestra Medical Technologies in the first quarter worth $6,853,000. Omega Fund Management LLC purchased a new position in shares of Kestra Medical Technologies in the first quarter worth $44,754,000. Alyeska Investment Group L.P. purchased a new position in shares of Kestra Medical Technologies in the first quarter worth $2,492,000. Finally, Caas Capital Management LP purchased a new position in shares of Kestra Medical Technologies in the first quarter worth $1,470,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.